Drug repurposing and repositioning as LCM strategy for CNS disorders

  • Created market scenario and identified low-hanging opportunities in terms of products and unmet needs

  • Provided a bespoke value proposition to access scientific proof to prioritise and benchmark indications

  • Helped narrow focus on the selected high-potential indications from the opportunity canvas

  • Identify key central nervous system (CNS) indications to repurpose its asset and position a new suite of offerings to maximise product uptake and patient adherence
  • Market assessment and evaluation of CNS disorders
    • Analysed disease landscape, patient journey and treatment options for different CNS disorders across geographies
    • Conducted a systematic literature review and detailed analysis of pre-clinical and clinical trial landscape across multiple CNS indications
  • Indication identification
    • Identified and selected valuable portfolio opportunities for optimising asset offerings
    • Assessed technological and feasibility challenges that needed to be addressed
    • Determined regulatory hurdles and other bottlenecks related to repositioning of drugs
  • Indication prioritisation
    • Conducted evidence-based indication prioritisation to navigate disease segmentation landscape
    • Benchmarked key indications and evaluated business opportunities in multiple indications
  • Identified a new patient pool for the client’s asset and created a bespoke value proposition considering scientific rationale, unmet needs, market positioning and scale of development
  • Evaluated business opportunities in multiple CNS indications based on growth potential, client’s current capabilities and gaps in the portfolio
  • Provided bespoke research support on key competitors and data evidence for patient adherence
Thank you for sharing your details

Your file will start downloading automatically

If it does not download within 1 minute,

Share this on